Lung Cancer: Targets and Therapy
Volume 15, 2024 - Issue
COMMENTARY
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC
Alexandria TM Lee1 Department of Medicine, University of California Irvine School of Medicine, Orange, CA, 92868, USA
https://orcid.org/0000-0002-2618-8131
https://orcid.org/0000-0002-2618-8131 & Sai-Hong Ignatius Ou2 Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USACorrespondence[email protected] [email protected]
https://orcid.org/0000-0002-1764-4975
https://orcid.org/0000-0002-1764-4975